Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson

Abstract Background Immune checkpoint inhibitors (ICPIs) are gaining increasing popularity as an efficacious treatment for advanced malignancies. ICPI treatment can be complicated by diarrhea and colitis. Systemic steroids are the first line treatment. Infliximab is reserved for severe refractory ca...

Full description

Bibliographic Details
Main Authors: Yinghong Wang, Hamzah Abu-Sbeih, Emily Mao, Noman Ali, Faisal Shaukat Ali, Wei Qiao, Phillip Lum, Gottumukkala Raju, Gladis Shuttlesworth, John Stroehlein, Adi Diab
Format: Article
Language:English
Published: BMJ Publishing Group 2018-05-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immune checkpoint inhibitor
Diarrhea
Colitis
Overall survival
Online Access:http://link.springer.com/article/10.1186/s40425-018-0346-6

Internet

http://link.springer.com/article/10.1186/s40425-018-0346-6

Similar Items